Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ESMO Asia 2023 | Enfortumab vedotin for the treatment of advanced urothelial cancer

Enrique Grande, MD, PhD, MD Anderson Cancer Centre Madrid, Madrid, Spain, provides the latest updates on enfortumab vedotin, a Nectin-4-binding antibody treatment for advanced bladder cancer. In line with the EV-301 trial (NCT03474107), testing enfortumab vedotin against chemotherapy, every single subgroup analysis has returned an advantageous result for patients. All patients consequently benefitted from enfortumab vedotin, regardless of PD-L1 status, cisplatin eligibility or geography. Whilst this is a hugely positive result, Dr Grande also discusses why this may make it difficult to assess which patients could benefit from this treatment specifically. This interview took place at the European Society for Medical Oncology (ESMO) Asia 2023 Congress in Singapore.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.